https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led

New real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with ove

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (a

The olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapi

The IMPACT-TD findings revealed:A majority of participants, regardless of age, reported a moderate t

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweigh

JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises t

Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Over

Truist Securities analyst Les Sulewski maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy

Teva to acquire Emalex for $700 million, posts Q1 earnings beat, and maintains 2026 outlook amid mar

Teva Pharmaceutical Indus (NYSE:TEVA) affirms FY2026 Adj EPS guidance from $2.57-$2.77 to $2.57-$2.7

Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.53 per share which beat the

The positive Phase 3 data of ecopipam in children with Tourette syndrome demonstrated statistically

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a B

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its bi

Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Over

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)

FDA accepts Teva's application for the monthly schizophrenia injection TEV-749 as shares show mi

Corcept Therapeutics shares plunged Thursday morning after a federal appeals court upheld a ruling t

https://www.cafc.uscourts.gov/opinions-orders/24-1346.OPINION.2-19-2026_2649652.pdf

Truist Securities analyst Les Sulewski maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy

Teva stock rises after a new study, in partnership with Sanofi, shows lasting benefits in ulcerative

Goldman Sachs analyst Matt Dellatorre maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy

Health Canada approves PrAJOVY® (fremanezumab solution for subcutaneous injection) for the preventio

Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweigh

Lawsuit claims Novo Nordisk delayed generic Victoza using patent tactics and settlements, preserving

Scotiabank analyst Louise Chen maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Sector Outp

Truist Securities analyst Les Sulewski maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy

Wall Street posted modest gains on Wednesday, while gold extended its relentless rally, shattering r

Teva beat fourth-quarter estimates as drug sales surged, led by Austedo and Ajovy, while the company

Teva Pharmaceutical Indus (NYSE:TEVA) is looking for FY2026 Adj EPS of $2.57-$2.77 vs $2.73 analyst

Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.96 per share which beat the

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),